Accelovance Inc is an award winning, clinical development CRO focused on vaccine, oncology, and general medicine Phase I-IV programs. As part of the transaction, it will assume management of THERAMetrics Inc.’s clinical program in the United States.
The team at Osborne Clarke that advised Accelovance Inc on all aspects of the acquisition was led by Partner Janita Good, who was assisted by Associate Samantha Peacock in the UK, Partner Martin Sundermann and Senior Associate Mark Friedrich in Germany and Partner Diego Rigatti and Senior Associate Pietro Giorgio Castronovo in Italy. Osborne Clarke was supported in Romania by Counsel Iustinian Captariu from Best Friend firm Kinstellar.
Janita Good, Partner at Osborne Clarke, said: “This transaction is a great example of the breadth and depth of our international life sciences expertise. Acting on all aspects of this complex transaction meant real cooperation between our US-based client and our experts in Germany, Italy, UK and Romania.
“Accelovance Inc is an award-winning, global CRO and an extremely dynamic business. This was first time we’ve acted for them and we can’t wait to see what they will do next.”
Stephen J. Trevisan, CEO of Accelovance said: “Having recently appointed Osborne Clarke, we can without a doubt say that their dedication and motivation exceeded our expectations. We relied heavily on them as trusted advisors throughout the entire process and look forward to working with them as we continue to grow. In the world of international business law, Osborne Clarke gives new meaning to “Keep Calm and Carry On.””
Corporate communications and press contacts
Connect with one of our experts
